How medical marijuana can help Crohn's disease

Medical Marijuana and Crohn's Disease

David Hua Author Profile

Cannabis for Crohn's Disease

A smiling white woman with long, flowing blonde hair wearing a sleeveless gray top.

Aria Biswas

Generic Blog Banner Image with Meadow Logo and text, 'The Easiest Way to Sell Cannabis Across Every Point of Sale' 

Cannabis Wellness

David Hua

Cannabis Retail

This article was originally published by Daniel Towns on the Meadow blog in November, 2014.

---

I had been using cannabis to alleviate my symptoms for nearly two years by the time a doctor diagnosed me with Crohn's Disease. It was the fall of 2010. I was a college sophomore at the time, with homecoming right around the corner. It was difficult to accept the fact that I suffered from a chronic condition, but I stayed in school thanks to prescription drugs and, as I've learned, thanks to cannabis.

Since 2010 I've experienced just one other flare-up of symptoms, the worst of which include ulcers, deficiencies caused by the malabsorbtion of nutrients, and the resultant fatigue that debilitates so many Crohn's patients.

I count myself lucky in the relative severity of my disease, which is itself extremely rare, because I have not yet undergone surgery for any life-threatening complications. Most patients with my condition will - and I may yet end up under the knife - but I argue that cannabis products significantly reduce that danger.

Many people have died at younger ages from aggressive, often untreatable Crohn's symptoms, so I feel more grateful for each healthy day at the age of twenty-four.

As a medical marijuana patient living in California, I have access to excellent medicine. Now that my home state of Oregon has followed its northern neighbor in legalization, I feel even more empowered to access treatment up and down this beautiful side of the country.

My patient journey was not always so easy, though. I arrived in the San Francisco Bay Area in the fall of 2009, without a medical marijuana recommendation, but I had already begun experiencing serious symptoms.
One year later, I reached my breaking point because of two legal drugs that are now completely off-limits for me. I did just about the worst thing any Crohn's patient could do: fighting a hangover with Advil.
Now I abstain from both alcohol and Ibuprofen because they can cause ulcers in a fragile gastrointestinal tract like mine. Before my diagnosis, however, I knew none of this.

I did know that one of the only ways I could eat in my condition was by smoking cannabis to achieve the increased appetite known colloquially as "the munchies."

In fact, I had eaten my most satisfying meals while medicated for years by that time, but flare-ups can exacerbate the suppressed appetite that afflicts many patients with inflammatory bowel disease.

My second and most recent flare-up occurred in the winter of 2013, and I was again prescribed a notorious little steroid known as Prednisone. This drug has a range of nasty effects including weight gain, difficulty sleeping, mood swings, and other harmful imbalances, and it can cause serious side effects if used in the long term.

After two regimens on Prednisone, I must admit that I felt much worse than I had at the height of any flare-up. Once again, cannabinoids helped me with pain while my intestines healed - this time, however, I was mostly suffering because I was weaning off of the steroids I had been prescribed.
My experience with cannabis as a treatment for Crohn's Disease is one of the biggest reasons that I'm excited to write for Meadow.

Cannabis was popular in ancient medicine as a cure for ailments of the stomach and digestion, but now we are truly living in a new age: medical researchers have finally begun to expose these hidden links with relation to Crohn's Disease.

Even with such high tradition in natural medicine, doctors and scientists explained the phenomenon very recently - the term 'endocannabinoid' was coined in the mid-1990s after a series of breakthroughs pinpointed THC-sensitive receptors in the brain.

These receptors were found to relate to a range of psychological and physiological responses that include the functioning of the gastrointestinal system. With the discovery of the endocannabinoid system, it became apparent that cannabis might achieve the transition from an ancient to a modern medicine.

What does this mean for patients with inflammatory bowel disease? Put simply, it explains how cannabis helps Crohn's patients to suppress symptoms like nausea, a cause of weight loss.

Increased appetite was a noticeable effect, but the evidence suggested calming and antispasmodic properties as well; people with IBD likely used cannabis to relieve pain, stress, and to help them sleep long before the discovery of the endocannabinoid system.

Following these implications, researchers began seriously investigating cannabis as a medication for Crohn's Disease in 2011, with promising initial results.

Here at Meadow, we strive to provide patients with accurate and objective posts on peer-reviewed research, which is why we've created this Cannabis Patient's Guide to Crohn's Disease.

Firstly, we do not recommend immediately adopting cannabis as a replacement for Crohn's medication prescribed by physicians.

Medical marijuana has been proven to reduce the need for medication in other diseases, and the same may be true for Crohn's Disease - however, we should wait for further research before moving in this direction.

In my experience, the best approach to controlling Crohn's Disease involves a combination of prescription drugs, cannabis, regular exercise, and a healthy diet.

On a side note, I do prefer certain pharmaceuticals over others, but some people suffering from a more aggressive case of Crohn's Disease may not benefit from my prescriptions.

With that said, medical researchers made impressive progress toward classifying cannabis as an approved treatment for Crohn's Disease in recent years.

The best scientific evidence for the effectiveness of cannabis as a Crohn's medication came in a series of three studies conducted between 2011 and 2013. Beyond the fact that each study included actual Crohn's patients using cannabis, each of the three publications is unique in terms of sample size, methodology, and reliability.

<figure>
![Cannabis as Crohn's Medication 2011-2013](//images.contentful.com/6kwu1u6s8j23/6nVfAes99ZQSP4DXnw4LTQ/b7b9de9f6440df6b4896acd8b6d2b570/Cannabis_as_Crohn-s_Medication_2011-2013.png)
  <figcaption>A graph showing the dates, sample sizes, and clinical response rates for three major studies of cannabis as a medication for Crohn's Disease</figcaption>
</figure>

In the first study, conducted by an Israeli team in August 2011, 30 participants rated their diseases on a scale called the Harvey Bradshaw index (also known as the Crohn's Disease Activity Index or CDAI).

After treatment with cannabis, 21 of the 30 "improved significantly," with the need for other medication also reduced. Remarkably, "15 of the patients had 19 surgeries during an average period of nine years before cannabis use, but only two required surgery during an average period of three years of cannabis use."

One of the most important benefits may be a reduction in the the number of surgeries undergone by Crohn's patients; the National Institutes of Health report that between 70% and 90% of these patients will require operations, of whom 39% require repeat operations.

While its results were promising, however, skepticism persisted in 2011 because this study was a first foray without the use of a placebo-controlled group. To their credit, the researchers did achieve impressive results as measured by the CDAI, which depends on both self-reported and observed criteria.

Later in 2011, a team of enteric scientists published a study of cannabis as a treatment for Crohn's Disease and Ulcerative Colitis (UC), two common varieties of inflammatory bowel disease.

The Crohn's group consisted of 191 patients, of whom 91 reported lifetime cannabis use - a rate of 48%. Of lifetime users, an impressive 50% used marijuana to relieve symptoms. The numbers compare similarly between UC and Crohn's patients in the study because cannabis treats similar problems caused by the two diseases.

To achieve these measures, the team employed a questionnaire "regarding current and previous cannabis use, socioeconomic factors, disease history and medication use, including complementary alternative medicines."
For disease activity they used the Short Inflammatory Bowel Disease Questionnaire, another systematic index measuring the health-related quality of life for Crohn's patients. As a survey of nearly 200 people, this study provided further evidence for the reclassification of medical marijuana as a Crohn's treatment.

It was not until 2013, however, that the journal Clinical Gastroenterology and Hepatology published the most definitive results yet achieved on the subject. In a placebo-controlled study of 21 Crohn's patients conducted over a period of ten weeks, 10 of the 11 subjects in the cannabis group induced a clinical response by smoking marijuana, with five even achieving complete remission.

The placebo group showed much lower rates in each category, providing a much-needed control for mounting evidence surrounding cannabis as a treatment for inflammatory bowel conditions.

With luck, these trials can provide the groundwork for a new series of experiments to prove the link between cannabis and Crohn's Disease beyond a reasonable doubt.

A review of medical literature published early in 2014 by the journal Pharmacology sought to do just that, highlighting the locations of cannabinoid receptors (classified as either CB1 or CB2) throughout the gastrointestinal tract and their potential clinical effects:

<figure>
![Crohns Disease IBD](//images.contentful.com/6kwu1u6s8j23/3afLmCLs6M4ouhAmekLP1z/3166e1ab4c2d992b64ea020bea1c7ab7/Crohns_Disease_IBD.png)
  <figcaption>Potential targets and mechanisms of CBs involved in the improvement of IBD. Natural and synthetic CBs act via intestinal CB1 and CB2 receptors to regulate epithelial permeability, motility, secretion (via the enteric nervous system), as well as leukocyte migration, recruitment and apoptosis. As the site with the highest CB1 expression (but also some CB2 expression), the brain may modulate motility, the sensation of pain and unpleasantness, thus positively influencing the inflammatory process. Source: Karger.</figcaption>
</figure>

Importantly, they emphasize that the brain is the principal site for CB1 expression and that CB2 has been detected in the brainstem. This means that the cannabis may reduce inflammation by acting on the central nervous system directly, perhaps influencing the sensation of pain, suppressing nausea, or relieving stress.

These conjectures make sense to me as a Crohn's patient, and researchers have long postulated that stress might cause symptoms to present. Paying respect to both ancient and modern wisdom, the review finds conclusively that cannabis has great potential as a treatment for Crohn's Disease. In their words, this "elegant translation" from natural to scientific medicine should set the stage for major discoveries in the near future.
Crohn's patients today may have the best chance at living normal lives seen thus far in the short history of this disease, and I believe that cannabis legalization could present another inflection point.

The research indicates that access to affordable cannabidiol and cannabis products could mitigate the pain and expense associated with Crohn's Disease, and public health officials, politicians, and dispensaries alike have taken notice.

If you suffer from inflammatory bowel disease and have not tried cannabis as a treatment for your symptoms, why not conduct your own clinical trials and report the results on one of the indices used in the studies?

No matter your background or condition, please recognize the mounting evidence for cannabis as a treatment for a range of conditions including Crohn's Disease - legalization may be able to prevent surgeries and even save lives.

---

Meadow builds software for the cannabis industry in California.

To learn more about Meadow, check us out on [Facebook](https://www.facebook.com/getmeadow), [Instagram](https://instagram.com/meadow.sf) and [Twitter](https://twitter.com/meadow).

Read one patient's report about using cannabis as medicine for Crohn's Disease

A Cannabis Patient's Guide to Crohn's Disease

__April 2016__

When we started Meadow in 2014, it was with a vision to make medical cannabis more accessible to patients in California. 

That seed of an idea soon grew into [Meadow Delivery](https://meadow.delivery "Meadow Cannabis Delivery") — what started as a medical cannabis delivery e-commerce site that quickly featured more than 45 California dispensaries and delivery partners spanning across 38% of California zip codes.

In February 2015 the business expanded to include [Meadow MD](https://meadowmd.com/ "Meadow MD"), a platform for medical cannabis doctor’s recommendations. Using Meadow MD, thousands of patients across California connected with independent physicians from the comfort of their homes.

The next branch of growth came with the launch of the Meadow Platform in November 2015, a [cannabis retail](https://getmeadow.com/blog/tags/cannabis-retail "cannabis retail") software suite for dispensaries and delivery services in California.

<figure>
![cannabis analytics and reporting](//images.ctfassets.net/6kwu1u6s8j23/6xLiWoOiHo3ZchQeqvOj4Q/4a0f4d9b010b4b84a4e3595e4a1f91a3/cannabis_analytics_and_reporting.png)
<figcaption> Meadow's analytics for dispensaries and delivery services. </figcaption>
  </figure>

Today we’re incredibly thrilled to announce even more exciting news.

Meadow has closed $2.1 million in seed funding from a group of incredible investors, including David Lee, YC partner Justin Kan, Reddit CEO and co-founder Steve Huffman, Reddit co-founder and YC Partner Alexis Ohanian, Angel Investor and Entrepreneur Hiten Shah, Slow Ventures, Liquid 2 Ventures, SOMA Capital, and Poseidon Asset Management.

We’re so grateful for these investors and their belief in our business, our growth trajectory and our values.

Today we’re also announcing the launch of our Cannabis Point-of-Sale and Inventory Management systems, the newest additions to Meadow Platform.
These systems have been built specifically for cannabis businesses, incorporating feedback and best practices from patients, dispensary partners, legislators and regulators across California.

### Why Does Cannabis Software Matter?
The cannabis industry is rife with complication.

Regulations governing medical cannabis businesses can be difficult to navigate and are often in flux. Therefore, many established companies have not built tools for cannabis businesses or developed services tailored to their needs.

Some have even dropped cannabis business clients once they learned the nature of their business.

This is where Meadow comes in. We understand, appreciate and value the cannabis industry and the far-reaching medical applications of cannabis. We also have our finger on the pulse of industry regulations.

__We’re creating solutions specifically for cannabis companies.__

<figure>
![turnkey cannabis software](//images.ctfassets.net/6kwu1u6s8j23/3e3cryVtcSyHMJmpyL99g9/12c042af714fe87427c545f38751ed51/turnkey_cannabis_software.png)
</figure>

<callout>“We’re replacing outdated software and tools made for other industries with technology built from the ground up for cannabis. We work closely with our partners to understand the pain points and intricacies of their operations and work with regulators to ensure legal compliance and best practices.” — Meadow CEO and Co-founder David Hua </callout>

### What Are We Going To Use the Money For?

We’ll continue to scale [getmeadow.com](https://getmeadow.com "getmeadow.com") and Meadow MD to continue to provide our patients with access to medical marijuana.

We’ve seen and experienced the benefits of medical cannabis firsthand and will continue to service our patients and partners with the highest quality products and services.

“We plan to connect the entire cannabis supply chain, from farm to flame. We have the opportunity to build technology that will become the backbone of this industry — in California and beyond — and we’re thrilled to have an incredible group of forward-thinking investors backing our mission.” — CEO David Hua

<figure>
![Meadow founders Y Combinator cannabis startup](//images.ctfassets.net/6kwu1u6s8j23/2ru5B8bxmT0mOLxu3o5SHF/f948ab74ffb49c89b9db81945e819c55/Meadow_founders_Y_Combinator_cannabis_startup.jpeg)
<figcaption>The Meadow Founders at a 2014 Y Combinator event in Palo Alto. From the left: Harrison Lee, Scott A Garman, Rick Harrison, and David Hua.</figcaption>
</figure>

Here’s what some of our investors have to say:

__Justin Kan — Y-Combinator Partner & Spokesperson, Founder Justin.tv/Twitch__

> With Meadow you have the combination of the right team, with the right product, at exactly the right time. We’re coming to a tipping point. Support for marijuana legalization has hit an all-time high. At YC we see software disrupting old industries all the time. Meadow is disrupting this budding new industry by bringing the dispensaries, customers and patients all to one platform.

__Alexis Ohanian — co-founder, Reddit, Y-Combinator Partner__

> We’re just beginning to unlock the medical, social, and economic benefits of cannabis and the results are already striking. Meadow is building world-class technology for a massive industry that’s only just starting to grow — the stakes have never been higher.

__Hiten Shah — co-founder at Quick Sprout and Crazy Egg, Angel Investor__

> I invested in Meadow because I believe in the team, their mission and the medicinal benefits of cannabis. I believe in David Hua and his team’s ability to create the best software for the cannabis industry that touches both cannabis businesses and the consumers interacting with them. I’m really excited to see this industry move forward with it’s potential to improve the lives of countless people. I believe Meadow will be a big part of the industry’s future with their software skills and, equally important, their compassion for the industry and it’s consumers.

__Emily Paxhia — Founding Partner & Director of Relations, Poseidon Asset Management__

> Our decision to invest in Meadow was based on the quality of the founders who brought true technology solutions to an underserved market. We also strongly believe Meadow’s platform and strategy works well with the regulations and optimizing the B2B experience. We appreciate that the team focuses on the quality of the product and understands how critical the political process is to the growth of a company in the cannabis industry. Their passion for the industry is translated into user-friendly and elegant platforms, which make the experience for patients and customers pleasant and efficient.

__Jeff Ferguson — President and co-founder @ PipelineDB, Angel Investor__

> I invested personally in Meadow because they are doing for the emerging cannabis industry what Uber did for transportation — take control of it by building great software.

### A Rising Tide Lifts All Ships
We would like to take this opportunity to thank all of our investors and our patients. Thank you for your support! We’re so excited to continue to grow with this dynamic industry, and we’re grateful to provide quality medicine to our patients.

__The cannabis movement and social justice are at the core of Meadow’s values and DNA.__ We’d like to thank everyone who has joined us in advocating on behalf of cannabis. We’d also like to thank those who join us at education events — let’s continue to hone our swords together.

<figure>
![David Hua, Steve DeAngelo and more cannabis industry leaders](//images.ctfassets.net/6kwu1u6s8j23/1cb49TURJ1i0b1ToDgddMb/b227229bbebfbcc3555e42268fc2040f/David_Hua_Steve_DeAngelo_and_more.jpeg)
<figcaption>David Hua, CEO and co-founder of Meadow; Steve DeAngelo, Founder and CEO of Harborside Health Center; Gavin Kogan Esq., attorney, political advocate and cannabis entrepreneur; and Emily Paxhia of Poseidon Asset Management at the Silicon Valley AgTech Conference in May 2015.</figcaption>
</figure>

__A special thanks to our teachers, mentors and partners. We stand on the shoulders of giants.__

A heartfelt thank you to: Steve DeAngelo, California Growers Association, Debby Goldsberry, the faculty at Oaksterdam, California Cannabis Industry Association, and The ArcView Group.

And a thank you to all of our partners, who are on the front lines everyday: The Apothecarium, SPARC, Vapor Room, and all of our other dispensary and delivery partners. We wouldn’t be here without you.

<figure>
![Cannabis Delivery Risk Mitigation](//images.ctfassets.net/6kwu1u6s8j23/7CoWPJlucRyIjKO83qdEH3/4a2108b3c5187debe18b8a6d88238abc/Cannabis_Delivery_Risk_Mitigation.jpeg)
  <figcaption>A recent event held at Meadow on Risk Mitigation and Driver Best Practices.</figcaption>
</figure>

### Stand with us on the right side of history.

To learn more about Meadow, check us out on [Instagram](https://instagram.com/meadow.sf "Meadow Instagram"), [LinkedIn](https://www.linkedin.com/company/getmeadow/ "LinkedIn") & [YouTube](https://www.youtube.com/c/Getmeadow/videos "Meadow YouTube").


Read more to learn about where we started

The Meadow Blog

Browse by tag:

A Cannabis Patient's Guide to Crohn's Disease

Meadow Raises $2.1 Million in Seed Funding To Grow Cannabis Retail Platform